[Hormonal therapy in metastatic breast cancer].
The primary objective in metastatic breast cancer is tumor control and symptom palliation. Factors to be considered are: efficacy, tolerance and quality of life as well as patient preferences. In the Hormone Receptor Positive Group, Hormonal treatment is the best choice because of it's effectiveness and good toxicity profile. Endocrine therapy has two main targets: the first one is to block estrogen production. In premenopausal women this can be through ovarian ablation. In postmenopausal women this is achieved by blocking the peripheral conversion of androgens to estrogens by blocking the enzyme known as aromatase. The other option is to block the action of the estrogen on it's receptor with the group of drugs known as selective estrogen receptor modulators (SERM). This class of drugs can be used in pre and postmenopausal women. Treatment should be tailored according to patient characteristics and menopausal status.
Martínez-Prieto
Marcela
M
Centro Médico ABC. marcelamtzp@hotmail.com
Flores de la Torre
Celia B
CB
Rivera Rivera
Samuel
S
Cruz Esquivel
Iván
I
D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010052:Ovariectomy
D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators